Waters Corporation
WAT Healthcare Diagnostics & Research
Waters Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 6.99% from fiscal 2024. In the quarter to June 2026, revenue grew 113.4%, EPS fell 156.3%, free cash flow grew 750.0% and total debt rose 308.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow WAT
Waters Corporation (WAT) Revenue
Waters Corporation's revenue for fiscal 2025 was $3.2B, up 6.99% from $3.0B in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.6B. Over the past ten years it has ranged from $2.0B (fiscal 2015) to $3.2B (fiscal 2025) — the current reading is the highest in ten years. Waters Corporation ranks 8th of 50 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $3.2B | 6.99% |
| FY2024 | $3.0B | 0.07% |
| FY2023 | $3.0B | (0.52%) |
| FY2022 | $3.0B | 6.68% |
| FY2021 | $2.8B | 17.78% |
| FY2020 | $2.4B | (1.71%) |
| FY2019 | $2.4B | (0.55%) |
| FY2018 | $2.4B | 4.80% |
| FY2017 | $2.3B | 6.54% |
| FY2016 | $2.2B | 6.12% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $1.6B | 29.83% |
| Mar 2026 | $1.3B | 35.89% |
| Dec 2025 | $932.4M | 16.57% |
| Sep 2025 | $799.9M | 3.75% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| IQV IQVIA Holdings Inc. compare | $17.0B |
| LH Labcorp Holdings Inc. compare | $14.3B |
| DGX Quest Diagnostics Incorporated compare | $11.6B |
| A Agilent Technologies, Inc. compare | $7.4B |
| WAT Waters Corporation | $4.6B |
| IDXX IDEXX Laboratories, Inc. compare | $4.6B |
| ILMN Illumina, Inc. compare | $4.5B |
| MTD Mettler-Toledo International, Inc. compare | $4.1B |
| NTRA Natera, Inc. compare | $2.7B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on WAT
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement